GEP20032902B - Mixture of Recombinant Vaccinia Vectors as Polyenv Vaccines for HIV - Google Patents

Mixture of Recombinant Vaccinia Vectors as Polyenv Vaccines for HIV

Info

Publication number
GEP20032902B
GEP20032902B GEAP19974458A GEAP1997004458A GEP20032902B GE P20032902 B GEP20032902 B GE P20032902B GE AP19974458 A GEAP19974458 A GE AP19974458A GE AP1997004458 A GEAP1997004458 A GE AP1997004458A GE P20032902 B GEP20032902 B GE P20032902B
Authority
GE
Georgia
Prior art keywords
hiv
recombinant vaccinia
mixture
polyenv vaccines
vaccinia vectors
Prior art date
Application number
GEAP19974458A
Other languages
English (en)
Inventor
Karen Slobod
Julia L Hurwitz
Randall J Owens
Christopher Coleclough
Original Assignee
St Jude Childrens Res Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by St Jude Childrens Res Hospital filed Critical St Jude Childrens Res Hospital
Publication of GEP20032902B publication Critical patent/GEP20032902B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
    • C07K14/155—Lentiviridae, e.g. human immunodeficiency virus [HIV], visna-maedi virus or equine infectious anaemia virus
    • C07K14/16—HIV-1 ; HIV-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24171—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
GEAP19974458A 1996-01-23 1997-01-23 Mixture of Recombinant Vaccinia Vectors as Polyenv Vaccines for HIV GEP20032902B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/590,288 US5741492A (en) 1996-01-23 1996-01-23 Preparation and use of viral vectors for mixed envelope protein vaccines against human immunodeficiency viruses

Publications (1)

Publication Number Publication Date
GEP20032902B true GEP20032902B (en) 2003-02-25

Family

ID=24361647

Family Applications (1)

Application Number Title Priority Date Filing Date
GEAP19974458A GEP20032902B (en) 1996-01-23 1997-01-23 Mixture of Recombinant Vaccinia Vectors as Polyenv Vaccines for HIV

Country Status (28)

Country Link
US (3) US5741492A (OSRAM)
EP (2) EP0876498B1 (OSRAM)
JP (2) JP2000504326A (OSRAM)
KR (1) KR100571479B1 (OSRAM)
CN (1) CN1229501C (OSRAM)
AP (1) AP1200A (OSRAM)
AT (1) ATE278790T1 (OSRAM)
AU (1) AU709174B2 (OSRAM)
BG (1) BG64711B1 (OSRAM)
BR (1) BR9707611A (OSRAM)
CA (1) CA2243570C (OSRAM)
CZ (1) CZ296575B6 (OSRAM)
DE (1) DE69731075T2 (OSRAM)
DK (1) DK0876498T3 (OSRAM)
EA (1) EA002390B1 (OSRAM)
ES (1) ES2230596T3 (OSRAM)
GE (1) GEP20032902B (OSRAM)
HU (2) HU0402182D0 (OSRAM)
IL (2) IL125497A (OSRAM)
NO (1) NO322261B1 (OSRAM)
NZ (1) NZ331024A (OSRAM)
OA (1) OA10814A (OSRAM)
PL (1) PL188641B1 (OSRAM)
PT (1) PT876498E (OSRAM)
RO (1) RO120268B1 (OSRAM)
TR (1) TR199801418T2 (OSRAM)
UA (1) UA73712C2 (OSRAM)
WO (1) WO1997027311A1 (OSRAM)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7488485B2 (en) * 2003-09-16 2009-02-10 University Of Kansas Medical Center DNA vaccine compositions and methods of use
US20030138454A1 (en) * 1997-06-09 2003-07-24 Oxxon Pharmaccines, Ltd. Vaccination method
GB9711957D0 (en) * 1997-06-09 1997-08-06 Isis Innovation Methods and reagents for vaccination
US6919318B1 (en) * 1998-04-22 2005-07-19 Chiron Corporation Enhancing immune responses to genetic immunization by using a chemokine
WO1999061049A2 (en) * 1998-05-22 1999-12-02 University Of Massachusetts Medical Center Model for infection by a pathogen using administration of nucleic acids
US6562800B1 (en) * 1998-10-30 2003-05-13 University Of Southern California Use of immunopotentiating sequences for inducing immune response
US6759237B1 (en) 1998-11-05 2004-07-06 The Trustees Of The University Of Pennsylvania Adeno-associated virus serotype 1 nucleic acid sequences, vectors and host cells containing same
CA2348382C (en) * 1998-11-10 2013-09-17 The University Of North Carolina At Chapel Hill Chimeric parvovirus vectors and methods of making and administering the same
JP4776075B2 (ja) * 1998-12-31 2011-09-21 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド 改変ｈｉｖｅｎｖポリペプチド
JP2002533124A (ja) * 1998-12-31 2002-10-08 カイロン コーポレイション Ｈｉｖポリペプチドの改善された発現およびウイルス様粒子の生成
US20030194800A1 (en) * 2001-08-31 2003-10-16 Megede Jan Zur Polynucleotides encoding antigenic HIV type B polypeptides, polypeptides and uses thereof
EP1141314A2 (en) * 1998-12-31 2001-10-10 Chiron Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
US7935805B1 (en) * 1998-12-31 2011-05-03 Novartis Vaccines & Diagnostics, Inc Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof
EP1144014B1 (en) * 1999-01-28 2005-07-27 Stichting Biomedical Primate Research Center Composition and method for obtaining specific immunisation against one or more antigens using different recombinant vectors
DE19907485B4 (de) * 1999-02-12 2008-01-17 Strathmann Ag & Co. Virus-Vakzine
US6420545B1 (en) * 1999-05-24 2002-07-16 The Trustees Of The University Of Pennsylvania CD4-independent HIV envelope proteins as vaccines and therapeutics
WO2001037878A2 (en) * 1999-11-29 2001-05-31 Orchid Biosciences, Inc. Methods of identifying optimal drug combinations and compositions thereof
AU2002211948B2 (en) 2000-03-02 2007-09-13 Emory University DNA expression vectors and methods of use
US20040105871A1 (en) * 2000-03-02 2004-06-03 Robinson Harriet L. Compositions and methods for generating an immune response
US8623379B2 (en) * 2000-03-02 2014-01-07 Emory University Compositions and methods for generating an immune response
CA2417240A1 (en) * 2000-08-07 2002-02-14 Sloan-Kettering Institute For Cancer Research Method and composition for immunization using mixed pools of mutated nucleic acids or peptides
WO2002080982A2 (en) * 2001-01-12 2002-10-17 Chiron Corporation Nucleic acid mucosal immunization
PT1372710E (pt) * 2001-03-08 2009-12-21 Us Gov Health & Human Serv Vam modificado que expressa os genes gag e pol do envelope de vih
AU2002320314A1 (en) 2001-07-05 2003-01-21 Chiron, Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
US20030198621A1 (en) * 2001-07-05 2003-10-23 Megede Jan Zur Polynucleotides encoding antigenic HIV type B and/or type C polypeptides, polypeptides and uses thereof
GB0118532D0 (en) * 2001-07-30 2001-09-19 Isis Innovation Materials and methods relating to improved vaccination strategies
US20030170614A1 (en) * 2001-08-31 2003-09-11 Megede Jan Zur Polynucleotides encoding antigenic HIV type B polypeptides, polypeptides and uses thereof
US20070269456A1 (en) * 2001-11-05 2007-11-22 Lasher Alfred W DNA-based plasmid formulations and vaccines and prophylactics containing the same
US20030228327A1 (en) * 2001-11-05 2003-12-11 Lasher Alfred W. DNA-based plasmid formulations and vaccines and prophylactics containing the same
WO2003047617A2 (en) 2001-11-30 2003-06-12 Isis Innovation Limited Vaccine
US7094410B2 (en) * 2002-03-02 2006-08-22 The Scripps Research Institute DNA vaccine against proliferating endothelial cells and methods of use thereof
US6923958B2 (en) * 2002-03-02 2005-08-02 The Scripps Research Institute DNA vaccines encoding CEA and a CD40 ligand and methods of use thereof
US20040106566A1 (en) * 2002-05-17 2004-06-03 Shi-Lung Lin RNA-splicing and processing-directed gene silencing and the relative applications thereof
DE60335755D1 (de) * 2002-07-18 2011-02-24 Univ Washington Pharmazeutische Zusammensetzungen, die immunologisch aktive Herpes simplex Virus Proteinfragmente enthalten
WO2004050856A2 (en) * 2002-12-03 2004-06-17 University Of Massachusetts Polyvalent, primary hiv-1 glycoprotein dna vaccines and vaccination methods
US7658927B2 (en) * 2003-05-12 2010-02-09 University Of Florida Research Foundation, Inc. Materials and methods for immunizing against FIV infection
AU2004238367A1 (en) * 2003-05-12 2004-11-25 University Of Florida Research Foundation, Inc. Materials and methods for immunizing against FIV infection
US8076060B2 (en) * 2003-08-04 2011-12-13 Emil William Chynn Vaccination and immunotherapy as new therapeutic modalities in the treatment of glaucoma
CA2537953A1 (en) * 2003-09-09 2005-03-17 Virxsys Corporation Lentivirus vector-based approaches for generating an immune response to hiv in humans
CN1913919B (zh) 2003-09-15 2011-10-19 美国政府健康及人类服务部 基于hiv多进化枝的env的hiv疫苗
EP1667631A4 (en) * 2003-09-15 2010-04-14 Novartis Vaccines & Diagnostic COMBINATION PATHS FOR GENERATING IMMUNE RESPONSES
US20050175627A1 (en) * 2003-09-24 2005-08-11 Oxxon Therapeutics Ltd. HIV pharmaccines
US7622125B2 (en) 2004-05-05 2009-11-24 Novartis Vaccines And Diagnostics, Inc. Polycistronic HIV vector constructs
WO2005117964A2 (en) 2004-05-27 2005-12-15 Centocor, Inc. Cynomolgus prostate specific antigen
US20050276758A1 (en) * 2004-06-15 2005-12-15 Marshall Deborah J Method for screening agents against human prostate disease
ATE527281T1 (de) * 2004-07-16 2011-10-15 Us Gov Health & Human Serv Impfstoffe gegen aids umfassend cmv/r nucleinsäurekonstrukte
US20080085261A1 (en) * 2004-10-19 2008-04-10 Haynes Barton F Vaccine Adjuvant
EP1814583A2 (en) * 2004-11-01 2007-08-08 Novartis Vaccines and Diagnostics, Inc. Combination approaches for generating immune responses
NZ555830A (en) * 2004-12-15 2009-01-31 Univ North Carolina Chimeric vectors
WO2008048984A2 (en) * 2006-10-18 2008-04-24 St. Jude Children's Research Hospital Methods and compositions for preparing a universal influenza vaccine
EP2396343B1 (en) 2009-02-11 2017-05-17 The University of North Carolina At Chapel Hill Modified virus vectors and methods of making and using the same
WO2012070974A1 (ru) * 2010-11-22 2012-05-31 Farber Boris Slavinovich Вакцины с повышенной иммуногенностью и способы их получения
US8703137B2 (en) 2011-01-31 2014-04-22 Intellect Neurosciences Inc. Treatment of tauopathies
AP2013007166A0 (en) 2011-04-06 2013-10-31 Univ Paris Descartes Inst De Rech Pour Le Dev Ird Pharmaceutical compositions for preventing and/or treating an HIV disease in humans
US9393300B2 (en) 2011-11-14 2016-07-19 Novartis Ag Immunogenic complexes of polyanionic carbomers and Env polypeptides and methods of manufacture and use thereof
WO2013126622A1 (en) 2012-02-24 2013-08-29 President And Fellows Of Harvard College Methods for displaying polypeptides and uses thereof
EP3390430B1 (en) * 2015-12-15 2019-08-28 Janssen Vaccines & Prevention B.V. Human immunodeficiency virus antigens, vectors, compositions, and methods of use thereof
CA3135170A1 (en) 2019-04-05 2020-10-08 Tauc3 Biologics Limited Anti-tauc3 antibodies and uses thereof
IT202100000569A1 (it) * 2021-01-14 2022-07-14 Evobiotech S R L Composizione comprendente vescicole extracellulari vegetali ingegnerizzate e suo impiego come vaccino

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5198214A (en) * 1983-08-31 1993-03-30 Stolle Research & Development Corporation Anti-mastitis polyvalent vaccine, method of administration and method for production thereof
GR862412B (en) * 1985-09-25 1987-01-23 Oncogen Vaccines and immuinoassays for acquired immune deficiency syndrome
EP0243029A1 (en) * 1986-04-08 1987-10-28 THE UNITED STATES OF AMERICA as represented by the Secretary United States Department of Commerce Recombinant vaccinia virus expressing human retrovirus gene
US5169763A (en) * 1986-04-08 1992-12-08 Transgene S.A., Institut Pasteur Viral vector coding glycoprotein of HIV-1
US5081226A (en) * 1986-12-30 1992-01-14 The United States Of America As Represented By The Department Of Health And Human Services Synthetic peptides sharing sequence homology with the HIV envelope protein
DE69031735T2 (de) * 1989-04-18 1998-03-12 Applied Biotechnology Inc Erzeugung von hybrid-genen und proteinen durch rekombination mittels viren
WO1992022641A1 (en) * 1991-06-14 1992-12-23 Virogenetics Corporation Immunodeficiency virus recombinant poxvirus vaccine
US5643578A (en) * 1992-03-23 1997-07-01 University Of Massachusetts Medical Center Immunization by inoculation of DNA transcription unit
EP0740704A1 (en) * 1994-01-27 1996-11-06 University Of Massachusetts Medical Center Immunization by inoculation of dna transcription unit
FR2728794B1 (fr) * 1994-12-30 1997-03-21 Rhone Merieux Vaccin recombinant aviaire a base de virus herpes aviaire, notamment contre la maladie de gumboro

Also Published As

Publication number Publication date
IL156919A0 (en) 2004-02-08
KR19990081931A (ko) 1999-11-15
CN1214083A (zh) 1999-04-14
NZ331024A (en) 2000-02-28
DE69731075D1 (de) 2004-11-11
AP1200A (en) 2003-08-29
HK1016218A1 (en) 1999-10-29
AU1829997A (en) 1997-08-20
DK0876498T3 (da) 2005-02-07
EA002390B1 (ru) 2002-04-25
US5846546A (en) 1998-12-08
JP2000504326A (ja) 2000-04-11
HUP9900389A2 (hu) 1999-06-28
EP0876498B1 (en) 2004-10-06
JP2007259870A (ja) 2007-10-11
EA199800638A1 (ru) 1999-02-25
PL328193A1 (en) 1999-01-18
AU709174B2 (en) 1999-08-26
DE69731075T2 (de) 2006-03-09
NO983377D0 (no) 1998-07-22
HU224344B1 (hu) 2005-08-29
CN1229501C (zh) 2005-11-30
IL125497A0 (en) 1999-03-12
US6086891A (en) 2000-07-11
RO120268B1 (ro) 2005-11-30
OA10814A (en) 2003-01-28
PT876498E (pt) 2005-02-28
EP1378516A1 (en) 2004-01-07
CA2243570A1 (en) 1997-07-31
HU0402182D0 (en) 2004-12-28
US5741492A (en) 1998-04-21
NO322261B1 (no) 2006-09-04
HUP9900389A3 (en) 2001-06-28
BG64711B1 (bg) 2005-12-30
BG102712A (en) 1999-04-30
KR100571479B1 (ko) 2007-06-07
PL188641B1 (pl) 2005-03-31
NO983377L (no) 1998-09-23
WO1997027311A1 (en) 1997-07-31
EP0876498A1 (en) 1998-11-11
AP9801325A0 (en) 1998-09-30
ATE278790T1 (de) 2004-10-15
CZ296575B6 (cs) 2006-04-12
CA2243570C (en) 2001-08-14
UA73712C2 (en) 2005-09-15
ES2230596T3 (es) 2005-05-01
IL125497A (en) 2007-07-04
CZ229398A3 (cs) 1998-12-16
TR199801418T2 (xx) 1998-10-21
BR9707611A (pt) 1999-07-27

Similar Documents

Publication Publication Date Title
GEP20032902B (en) Mixture of Recombinant Vaccinia Vectors as Polyenv Vaccines for HIV
DK0835133T3 (da) Rekombinant koppevirus-rabies-præparater og kombinationspræparater samt anvendelser deraf
AU3636189A (en) Hiv-2 virus variants
NO912825D0 (no) Fremgangsmaate for fremstilling av cokonjugate vaksiner omfattende immunogenisk protein, hiv-beslektede peptider og anioniske grupper.
CA2189882A1 (en) Papillomavirus vaccines
PH25747A (en) Recombinant vaccinia vrus mva
CA2164818A1 (en) Tandem synthetic hiv-1 peptides
FI951138A7 (fi) Puuttellisia adenovirusvektoreita ja niiden käyttö geeniterapiassa
DE69233186D1 (de) Karcinoembryonale antigen expremierende rekombinante viren und methoden ihrer anwendung
CA2011878A1 (en) Immunogenic regions on the e7 protein of human papillomavirus type 16
EP0342860A3 (en) Novel protein, sequences containing the gene therefore, vectors, methods of preparation and use
AU580059B2 (en) Vaccine against rabies and preparation process thereof
DK0831899T3 (da) Rekombinant koppevirus-calicivirus-præparater og anvendelser
NZ239948A (en) Hiv gp160 modified at positions 502 and 510, vaccines and recombinant methods for producing modified gp160
CA2210294A1 (en) Immunogenic compositions containing recombinant attenuated poxviruses expressing htlv antigens
AU7890687A (en) DNA sequence vectors, recombinant viruses and method which employs recombinant vaccinia viruses capable of multiplying in CHO cells
AU8976691A (en) Selected peptides of the group-specific antigen (gag) of human immunodeficiency virus (hiv), the preparation and use thereof
EP0311228A3 (en) Recombinant polypeptides and their uses, including assay for aids virus
DE69726602D1 (en) Hepatitis b inhibitoren
CA2072982A1 (en) Hepatitis a vaccines
ZA915626B (en) Coconjugate vaccines comprising immunogenic protein,hiv related peptides,and anionic moieties
AU1814792A (en) Immunogenic peptides or polypeptides of the bvd virus and related viruses, vaccines incorporating them or expressing them, methods and means of production thereof
EP0816507A4 (en) NEW RECOMBINANT GEN
AR008998A1 (es) Polipeptidos de envoltura de hiv y vacuna.